ClinicalTrials.gov record
Suspended Phase 2 Interventional

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

ClinicalTrials.gov ID: NCT05756556

Public ClinicalTrials.gov record NCT05756556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Open-label Study of T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Study identification

NCT ID
NCT05756556
Recruitment status
Suspended
Study type
Interventional
Phase
Phase 2
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Enrollment
68 participants

Conditions and interventions

Interventions

  • T3011 + Cobimetinib Combination Product

Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2024
Primary completion
Dec 30, 2026
Completion
Dec 31, 2026
Last update posted
Jan 31, 2024

2024 – 2027

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Gabrail Cancer and Research Center Canton Ohio 44718

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05756556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2024 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05756556 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →